Understanding Which TB Drug Does Not Cross BBB and Why It Matters
•
3 min read
Tuberculous meningitis (TBM) accounts for 1% to 2% of all active TB cases, yet it is one of the most devastating forms of the disease. A major challenge in treating TBM is the delivery of drugs across the highly selective blood-brain barrier (BBB), which prevents many standard antitubercular medications from reaching effective concentrations in the central nervous system (CNS). Understanding which TB drug does not cross BBB is therefore crucial for effective therapeutic management.
